It targets cancer cells in vitro (against HepG2 cells) 14 times more specific than cisplatin via downregulating the expression c-Myc, hTERT, and Bcl-2 with 73%, 52%, and 90%, respectively, and its in vivo inhibition of tumor growth was as good as that of cisplatin. This evidence concerns the gene MYC and cancer.